Aytu BioPharma, Inc. (AYTU) Q3 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals declining revenues in ADHD and Pediatric portfolios, a decrease in cash reserves, and a negative adjusted EBITDA. Although EXXUA's launch shows promise, the overall financial performance is weak. The Q&A session highlights potential but lacks concrete data, and management's responses were somewhat vague. Despite some positive anecdotes and potential for geographic expansion, the strategic shift and financial challenges overshadow these positives, leading to a negative sentiment.
Key Financial Performance
Net Revenue Net revenue for the third quarter of fiscal 2026 was $12.4 million, a decrease of $6 million or 33% year-over-year compared to $18.5 million in the prior year period. The decrease was attributed to a strategic shift in sales force focus towards EXXUA, the launch of a generic version of an ADHD product, and payer changes affecting the Pediatric Portfolio.
EXXUA Revenue EXXUA contributed $2.4 million in the quarter. This was the first meaningful quarter of launch activity, with prescriptions and channel stocking contributing to the revenue. The launch included only a partial period of full sales force support.
ADHD Portfolio Revenue The ADHD portfolio generated $9.1 million in the third quarter compared to $15.4 million in the prior year period, a decrease driven by a strategic shift in focus towards EXXUA and the introduction of a generic version of Adzenys.
Pediatric Portfolio Revenue The Pediatric Portfolio generated $0.9 million for the third quarter compared to $3.1 million in the prior year period. The decrease was due to payer mix changes resulting in higher rebates and an increase in returns.
Gross Profit Margin Gross profit margin was 61% in the third quarter of fiscal 2026 compared to 69% in the same quarter last year. The decrease was impacted by a $700,000 inventory write-down related to the shift from branded Adzenys products to an authorized generic.
Adjusted EBITDA Adjusted EBITDA was negative $2.8 million for the third quarter of fiscal 2026 compared to a positive $3.9 million in the prior year period. The change was due to planned investments in the EXXUA launch and reduced marketing for the ADHD portfolio.
Cash and Cash Equivalents Cash and cash equivalents were $26.7 million at March 31, 2026, compared to $30 million at December 31, 2025, and $31 million at June 30, 2025. The decrease reflects planned investments in the EXXUA launch and normal working capital movements.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
EXXUA Launch: EXXUA, a selective serotonin 5-HT1A receptor agonist for major depressive disorder (MDD), was commercially launched. Over 1,300 prescriptions were written in Q3, with sequential monthly growth from 200 in January to 700 in March. April saw 920 prescriptions, a 26% month-over-month growth. Over 450 unique prescribers have adopted EXXUA, representing 10-13% of the target prescriber universe. Gross unit sales in Q3 were 3,335 units, generating $2.4 million in revenue.
MDD Market Opportunity: EXXUA targets the MDD market, addressing unmet needs with a novel mechanism of action. The launch strategy focuses on high-value psychiatry practices and targeted prescribers, leveraging RxConnect to reduce access barriers. Early adoption and refill activity indicate growing physician and patient interest.
Operational Efficiency: The phased deployment of the sales team and disciplined investment in EXXUA launch activities have been key. RxConnect ensures smooth access for patients and prescribers, while the legacy ADHD and Pediatric portfolios continue to generate cash to support EXXUA's growth.
Strategic Shift to CNS: Aytu is transitioning focus from legacy ADHD and Pediatric portfolios to the CNS market, with EXXUA as the centerpiece. ADHD net revenue decreased due to reduced promotional focus and generic competition, while the Pediatric portfolio remains a smaller, profitable segment.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decline: Net revenue decreased by $6 million (33%) year-over-year, primarily due to a strategic shift in sales force focus towards EXXUA and the introduction of generic competition for Adzenys.
Gross Margin Decline: Gross profit margin dropped from 69% to 61%, impacted by a $700,000 inventory write-down and the shift from branded to generic Adzenys products.
Launch Investment Costs: Increased operating expenses due to planned investments in the EXXUA launch, including sales and marketing, service costs, and launch infrastructure.
Pediatric Portfolio Revenue Decline: Net revenue for the Pediatric Portfolio decreased from $3.1 million to $0.9 million, impacted by payer mix changes and increased returns.
ADHD Portfolio Revenue Decline: Net revenue for the ADHD portfolio decreased from $15.4 million to $9.1 million, driven by reduced promotional focus and generic competition.
Cash Burn: Cash and cash equivalents decreased from $30 million to $26.7 million during the quarter, reflecting planned investments in the EXXUA launch and working capital movements.
Gross-to-Net Variability: Gross-to-net dynamics for EXXUA are still settling, with early access programs and payer mix creating variability in revenue recognition.
Operational Risks: The company is navigating payer changes, early access friction for EXXUA, and variability in prescription and revenue alignment during the launch phase.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
EXXUA Launch: The launch of EXXUA, a selective serotonin 5-HT1A receptor agonist for major depressive disorder, is progressing well with encouraging early adoption. Over 1,300 prescriptions were written in Q3, with a sequential growth in prescriptions from January to March. The company is focusing on high-value psychiatry practices and leveraging RxConnect to support access and reduce friction.
Sales Strategy: The sales strategy is disciplined, focusing on targeted prescribers and efficient resource allocation. The phased deployment of the sales team is intentional, with a focus on high-prescribing psychiatry practices. The company is not trying to outspend competitors but is focusing on prescribers who understand the unmet need and EXXUA's differentiated profile.
Market Opportunity: EXXUA is positioned to address a significant unmet need in the major depressive disorder market. The company is targeting a universe of 3,500 to 4,000 prescribers, with early adoption by 10% to 13% of this target group. The product's novel mechanism of action is resonating with prescribers.
Legacy Portfolios: The ADHD and Pediatric portfolios continue to generate cash, providing a foundation for investment in EXXUA. The ADHD portfolio generated $9.1 million in Q3, while the Pediatric portfolio generated $0.9 million. The company is strategically shifting focus towards EXXUA while maintaining cash generation from legacy products.
EXXUA Revenue Expectations: EXXUA generated $2.4 million in revenue in Q3, ahead of internal expectations. The company expects continued growth in prescriptions and unit sales, with gross-to-net dynamics still settling. The revenue model is expected to normalize as the launch matures.
Financial Model: The company expects mid- to high 60% gross margins over time, with a disciplined operating expense base. The path to profitability is anticipated as EXXUA revenue builds on top of the existing platform. Sales and marketing spend is expected to increase by $1 million to $2 million in the next quarter.
Market Dynamics: The company is seeing positive payer dynamics, with good coverage of EXXUA among commercial plans and increasing Medicaid and Medicare scripts. The launch investment framework remains disciplined, aligning spend with performance and cash flow.
Future Investments: The company plans to continue investing in scientific engagement, KOL development, peer-to-peer programs, and publication and medical congress activity to support EXXUA's growth. Online promotional campaigns are being launched to drive awareness and adoption.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Is the assumption of $1.5 million in 'stocking revenue' for EXXUA in the quarter accurate?
A:Yes, that is a pretty accurate calculation.
Q:What feedback has been received regarding weight gain and sexual side effects from physicians?
A:Regarding weight gain, it is too early to observe significant changes, but nothing unexpected has been reported. For sexual side effects, there have been very positive anecdotes, including restored libido and life-changing experiences.
Q:What is the prescribing activity of non-customers who have not been called on?
A:There has been significant prescribing activity from states without a physical presence, with prescriptions in 41 or 42 states. This has been highly encouraging, with some prescribers finding the product without any promotion.
Q:What percentage of prior authorizations for EXXUA are getting approved on the first pass?
A:Over 70% of prior authorizations are getting approved on the first pass, with approval rates improving month-on-month.
Q:What line of therapy are patients on when prescribed EXXUA?
A:Patients are generally between third and fifth line of therapy, with some being prescribed as early as second line. Approximately 60% of patients are being switched from another therapy.
Q:What is the typical prescription duration for EXXUA, and how are refills managed?
A:Patients typically start with a 14-day titration pack, followed by a 30-day supply. Afterward, they may receive prescriptions for 3 or 6 months. Refill rates are very encouraging.
Q:What is the company's plan for geographic expansion?
A:The company is actively considering expanding into select markets earlier than anticipated, focusing on areas with significant prescribing activity or access opportunities.
Q:Review of Unclear Management Responses
A:Management avoided providing specific percentages or detailed data on the exact breakdown of therapy lines (e.g., second, third, or fourth line) for EXXUA patients. Additionally, while they mentioned positive anecdotes and general trends, they did not provide concrete data or studies to substantiate claims about efficacy or patient outcomes.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
MDD
Pediatric Portfolio
Physicians
activity EXXUA
adoption
base
channel partner
day
demand
deployment sale
dynamic
force support
investment
launch
legacy portfolio
measure
model
peer
period decrease
prescriber
prescribing
refill activity
sale force
shift
stage
stockholder equity
therapy
titration pack
titration unit
treatment
unit count
unit sale
universe
AYTU Transcript
Aytu BioPharma, Inc. (AYTU) Q3 2026 Earnings Call Transcript
Unknown5-13
The earnings call reveals declining revenues in ADHD and Pediatric portfolios, a decrease in cash reserves, and a negative adjusted EBITDA. Although EXXUA's launch shows promise, the overall financial performance is weak. The Q&A session highlights potential but lacks concrete data, and management's responses were somewhat vague. Despite some positive anecdotes and potential for geographic expansion, the strategic shift and financial challenges overshadow these positives, leading to a negative sentiment.
Aytu BioPharma, Inc. (AYTU) Q2 2026 Earnings Call Transcript
Unknown2-3
The earnings call presents a mixed picture. While the EXXUA launch is on track and has potential, the current financials show declining revenue, margins, and a net loss. The Q&A reveals mixed feedback on EXXUA prescriptions and no immediate plans for sales force expansion, indicating cautious optimism. The strong gross margin and stable cash reserves are positives, but the overall sentiment remains neutral due to financial weaknesses and uncertainties.
Aytu BioPharma, Inc. (AYTU) Q1 2026 Earnings Call Transcript
Unknown11-13
The earnings call summary presents mixed signals. Basic financials show decreased net revenue in some areas but improved gross margins. The EXXUA product development and market strategy are promising, but the guidance lacks clarity, and the Q&A reveals uncertainties in realignment and payer engagement. Despite a positive outlook for EXXUA, current financial health and lack of detailed guidance temper optimism, leading to a neutral sentiment.
Aytu BioPharma, Inc. (AYTU) Q4 2025 Earnings Call Transcript
Unknown9-23
The earnings call presents mixed signals: while there is positive growth in the pediatric portfolio and improved cash position, gross margins have decreased and net losses remain significant. The Q&A reveals strategic plans for future launches but also highlights potential uncertainties, like selective payer engagement. Overall, these factors balance out to a neutral sentiment, with no strong catalysts for a significant stock price movement in either direction.
AYTU Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
